This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Amedisys (AMED) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Amedisys, Colgate-Palmolive, Deutsche, Societe General and Danske highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Amedisys, Colgate-Palmolive, Deutsche, Societe General and Danske highlighted as Zacks Bull and Bear of the Day
Zacks.com featured highlights include: Amedisys, Marine Products, Foot Locker, Systemax and Comfort Systems
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, Marine Products, Foot Locker, Systemax and Comfort Systems
Bull of the Day: Amedisys (AMED)
by Madeleine Johnson
After blowout earnings, can this top hospice provider push higher?
Bet on DuPont Analysis With 5 Top-Ranked Stocks
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation? Bet on these five stocks.
Amedisys (AMED) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amedisys, Inc. (AMED).
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.
5 Stocks to Gain as Fed Chair "Blinks" on Rates
by Swarup Gupta
Investors would now best prepare for sunnier days ahead, which make it imperative to pick select growth stocks.
Amedisys (AMED) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Falling Estimates & Price Mean for DaVita (DVA)
by Zacks Equity Research
DaVita (DVA) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Why Amedisys (AMED) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Amedisys (AMED).
Bright Outlook for Outpatient and Home Healthcare Industry
by Zacks Equity Research
Here we discuss how outpatient and home healthcare have been creating opportunities for investors keen on parking their money in this space.
Zacks.com highlights: Robert Half International, Children' Place, Amedisys, Foot Locker and Comfort Systems USA
by Zacks Equity Research
Zacks.com highlights: Robert Half International, Children's Place, Amedisys, Foot Locker and Comfort Systems USA
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
5 Quality Stock Picks Screened on DuPont Analysis
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.
5 Low Leverage Stocks You Can Safely Add to Your Portfolio
by Zacks Equity Research
One should keep in mind that debt financing remains a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate
Is Amedisys (AMED) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
4 Quality Stocks to Counter Market Volatility
by Zacks Equity Research
With the markets currently facing a lot of gyration, investing in quality stocks seems prudent. After all, these stocks provide excellent risk-adjusted returns.
US Stocks Enjoy Highest Post-Midterm Gains Since 1982: 5 Picks
by Swarup Gupta
A large swathe of market watchers thinks that a gridlocked Congress will be beneficial for U.S. equity markets.
New Strong Buy Stocks for November 7th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Zacks.com highlights: Core-Mark Holding, CACI International, Amedisys, Cadence Design Systems and WNS Holdings
by Zacks Equity Research
Zacks.com highlights: Core-Mark Holding, CACI International, Amedisys, Cadence Design Systems and WNS Holdings
The Zacks Analyst Blog Highlights: Archer-Daniels-Midland, Best Buy, Heidrick & Struggles International, Amedisys and RH
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Archer-Daniels-Midland, Best Buy, Heidrick & Struggles International, Amedisys and RH
5 Top-Ranked Momentum Stocks Driven by Driehaus Strategy
by Zacks Equity Research
Investors who have the tendency to take a high level of risks can choose momentum stocks using Driehaus strategy.
5 Top-Ranked Stocks Driven by DuPont Analysis
by Sanghamitra Saha
Here's why you should have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.